This headline suggests that AEON Biopharma's ABP-450 may be a strong biosimilar candidate to AbbVie's BOTOX, showing comparable stability under stress. This could significantly impact the competitive landscape for neurotoxin treatments, potentially creating a new revenue stream for AEON and a competitive threat for AbbVie.
The comparable degradation rates and methionine oxidation patterns under thermal stress are a positive early indicator for ABP-450's biosimilarity to BOTOX. If the multi-lot comparability study in H1 2027 confirms these findings, AEON Biopharma could pose a significant competitive threat to AbbVie's lucrative BOTOX franchise. This would be a major catalyst for AEON, potentially leading to increased market share and revenue in the neurotoxin market. For AbbVie, it represents a risk of erosion of their market dominance and pricing power for BOTOX. Investors should monitor the progress of AEON's comparability study closely.